acamprosate + naltrexone

acamprosate + naltrexone-University of Yalova refers to the pharmacological intervention arm of a clinical trial conducted by the University of Yalova (NCT05843838) for the treatment of Alcohol Use Disorder. This combination therapy utilizes two established medications: acamprosate, which is thought to restore the balance between glutamate and GABA neurotransmission by acting as an NMDA receptor antagonist and GABA-A receptor modulator, and naltrexone, a mu-opioid receptor antagonist that reduces the reinforcing effects of alcohol consumption. The trial specifically investigates the efficacy of these medications when used as a standard of care alongside a novel gamified mobile application designed to modify attentional bias toward alcohol-related cues, aiming to reduce cravings and drinking severity.

Other names

Akamprosat + Naltrekson